EBITDA grew 29% to Rs 928 crore, whereas web revenue for the interval stood at Rs 85 crore, up 428% year-over-year as towards a lack of Rs 16 crore in the identical interval final monetary 12 months, the corporate mentioned in a discover to the inventory exchanges.
“With the Board approval of the settlement of structured debt obligations, we’ll strengthen our stability sheet, improve monetary flexibility, and enhance profitability,” mentioned Kiran Mazumdar-Shaw, Chairperson, Biocon Group.
“Our partnership with the State of California via Civica Inc beneath the CalRx initiative, marks a landmark step in increasing reasonably priced insulin entry within the US, with potential to increase to different states,” she mentioned. “With a resilient basis, differentiated portfolio, and clear technique, we’re properly positioned to maintain progress and ship long-term worth to our stakeholders,” Shaw added.
The corporate’s generics enterprise continued its regular efficiency in Q2 with a progress of 24% pushed primarily by an uptick in just lately launched merchandise within the US and EU, in addition to progress within the generic formulations base enterprise, and the API enterprise.
“A key spotlight of this quarter was the inauguration of Biocon’s first OSD manufacturing facility in america, a major step in direction of increasing entry to our vertically built-in portfolio for sufferers within the area. We commenced filings for Semaglutide (gOzempic) in numerous markets, together with Canada and Brazil,” mentioned Siddharth Mittal, CEO & Managing Director, Biocon Restricted.Biocon Biologics posted 25% year-on-year income progress in Q2 and an over 40% improve in EBITDA. Sequentially, revenues grew 11%, pushed by market share enlargement in key remedy areas and profitable new product launches. “Within the US, we proceed to increase entry to biosimilars by leveraging the energy of our industrial platform. In FY26, we launched 4 biosimilars throughout key international markets and stay on observe for the bDenosumab launch,” mentioned Shreehas Tambe, CEO & Managing Director, Biocon Biologics.
